Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to an approval in China, according to FiercePharmaAsia. The company's majority-owned unit, Hutchison MediPharma Ltd. R&D, said the secondary efficacy endpoints, including objective response rate, disease control rate and overall survival, are still being monitored. The trial compared fruquintinib against a placebo in patients with metastatic colorectal cancer. More from FiercePharmaAsia